Is VivoSim Labs, Inc. (VIVS) a Buy, Sell, or Hold?
NASDAQ : VIVS
VivoSim Labs, Inc.
$0.468 USD
$0.14 (41.86%)
- Volume
- 97.92M
- Average Volume
- 3.23M
- Market Capitalization
- $1.2M
- P/E Ratio
- -0.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.30
- Year Low
- $0.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.38
Company Overview
NASDAQ
Keith Murphy
Biotechnology
Healthcare
VIVS
15
US
USD
Liquidity Metrics
-0.41
2.38
2.38
1.80
0.00
Sales & Valuation
$131K
9.18
-1.10
-0.11
-4.18
Profitability
-$5.35
-$13.84M
-10567.18%
-10565.65%
-277.62%
-187.42%
P/E Metrics
-0.06
0.00
0.00
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-72.93
1/9
$3.84M
$7.39M
$8.48M
-$13.83M
Key Metrics (TTM)
-$3.37M
-25.76
0.25
2.38
-277.62%
-227.56%
-1142.79%
-900.66%
1497 days
Company Executives
| Name | Title |
|---|---|
| Norman Staskey | President, Chief Financial Officer & Principal Financial Officer |
| Keith E. Murphy | Executive Chairman & Corporate Secretary |
| Tony Lialin | Chief Commercial Officer |
| Amar A. Sethi | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About VivoSim Labs, Inc. (NASDAQ:VIVS) Stock
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functi ... onal 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
VivoSim Provides Financial and Listing Compliance Update
2026-08-06 08:05:00
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders' equity of $2.5M. Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14, 2026 (the “Form 10-K”), the Company received a $5.0 million milestone payment from Eli Lilly and Company, and $1.0 million of additional cash was released from escrow on July 22, 2026, both in connection with the Company's previous sale of its FXR program to Eli Lilly and Company.
2026-07-21 08:05:00
Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market Initial customer wins bring VivoSim's human-relevant liver and GI testing to the world's second-largest pharmaceutical market
2026-07-16 08:30:00
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 4,705,883 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,705,883 shares of common stock at an effective combined price of $0.85 per share and accompanying common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.85 per share, will become exercisable immediately following receipt of shareholder approval and will expire five years from the initial exercise date.
2026-07-15 08:05:00
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly.
2026-06-29 08:05:00
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology's annual conference.
2026-06-29 08:05:00
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)
Frequently Asked Questions
-
What is the current VivoSim Labs, Inc. (VIVS) stock price?
-
VivoSim Labs, Inc.(NASDAQ:VIVS) stock price is $0.468 in the last trading session. During the trading session, VIVS stock reached the peak price of $5.3 while $0.3086 was the lowest point it dropped to. The percentage change in VIVS stock occurred in the recent session was 41.86% while the dollar amount for the price change in VIVS stock was $0.14.
-
VIVS's industry and sector of operation?
-
The NASDAQ listed VIVS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VIVS?
-
Norman Staskey | President, Chief Financial Officer & Principal Financial Officer
Keith E. Murphy | Executive Chairman & Corporate Secretary
Tony Lialin | Chief Commercial Officer
Amar A. Sethi | Chief Scientific Officer
| -
How many employees does VIVS have?
-
Number of VIVS employees currently stands at 15. VIVS operates from 11555 Sorrento Valley Road, San Diego, CA 92121, US.
-
Link for VIVS official website?
-
Official Website of VIVS is: https://vivosim.ai
-
How do I contact VIVS?
-
VIVS could be contacted at phone #858 224 1000 and can also be accessed through its website. VIVS operates from 11555 Sorrento Valley Road, San Diego, CA 92121, US.
-
How many shares of VIVS are traded daily?
-
The average number of VIVS shares traded daily for last 3 months was 3.23M.
-
What is the market cap of VIVS currently?
-
The market value of VIVS currently stands at $1.2M with its latest stock price at $0.468